消费者体验需求的提升促使零售商不断探索新渠道模式,以提高原有实体店效益的同时优化线上经营策略。本文分别考虑传统BORO(buy online and return online)和开通BOPS(buy online and pickup in store)两种渠道情形,构建零售商针对消费...消费者体验需求的提升促使零售商不断探索新渠道模式,以提高原有实体店效益的同时优化线上经营策略。本文分别考虑传统BORO(buy online and return online)和开通BOPS(buy online and pickup in store)两种渠道情形,构建零售商针对消费者线上购买并在线上或线下退款的差异化退货策略利润模型,分析两种渠道情形下的最优定价和最优退货策略,进而考虑BOPS渠道的溢出效应,分析零售商在相同退货策略下是否应该开通BOPS渠道。结果表明:(1)在两种情形下,随着线下商店数量的增多,零售商均会倾向于在低开店成本下选择全额退款策略,倾向于在高开店成本下选择部分退款策略;(2)在同渠道情形下,全额退款策略的定价始终低于部分退款策略。在同退货策略下,BOPS情形下的定价始终低于BORO情形;(3)高溢出效应和多商店数量都促使零售商选择开通BOPS渠道,但商店数量决定了BOPS线下麻烦成本规模因子对零售商开通BOPS渠道起推动还是抑制作用。本文为既定商店数量下多渠道零售商退货策略与渠道选择提供了决策支持。展开更多
Background:Kidney renal clear cell carcinoma(KIRC),a prevalent urological malignancy,represents about 3%of all adult malignancies.KIRC,accounting for~75%of renal malignancies,has poor prognosis in metastatic stages.Id...Background:Kidney renal clear cell carcinoma(KIRC),a prevalent urological malignancy,represents about 3%of all adult malignancies.KIRC,accounting for~75%of renal malignancies,has poor prognosis in metastatic stages.Identifying robust prognostic markers remains urgent.Block of proliferation 1(BOP1),a WD40-repeat protein,is implicated in cancer pathogenesis,but its role in KIRC is unclear.This study aimed to characterize BOP1 expression in KIRC and evaluate its prognostic value.Methods:BOP1 transcriptional levels were assessed through TCGA-KIRC RNA sequencing datasets.ROC curve construction was implemented via R statistical packages for diagnostic evaluation.Patient survival outcomes were visualized through Kaplan-Meier plotting with log-rank testing.Multivariate logistic regression models quantified associations between BOP1 expression and clinicopathological parameters.TIMER algorithm analyzed immune microenvironment composition.Genomic alterations and epigenetic modifications were investigated using cBioPortal and MethSurv platforms respectively.BOP1 protein levels in 786-O clear cell renal cell carcinoma(ccRCC)versus HK-2(normal renal)cell lines were validated by immunoblotting.Results:Evaluation of the TCGA database demonstrated that BOP1 mRNA abundance was higher in tumor specimens than in corresponding adjacent tissues.Patients with KIRC who had high BOP1 expression had differential overall survival(OS),disease-specific survival(DSS),and disease-free interval(DFI).BOP1 expression accurately recognised tumour tissues versus normal tissues(AUC=0.858),and the area under the ROCs for survival at 1,3,and 5 years were all greater than 0.6.The BOP1 gene variant rate was<1%.Out of the 15 DNA methylation CpG sites examined,7 exhibited prognostic significance in KIRC.BOP1 displayed a distinct relationship with immune cell infiltration in KIRC.The 786-O experimental group exhibited substantially higher BOP1 expression,as confirmed by Western blot detection.Conclusion:This study indicates that heightened BOP1 expression is linked to an adverse prognosis in KIRC,establishing it as an independent risk factor for this disease.These findings establish BOP1 as a novel and independent prognostic biomarker for KIRC,offering potential clinical utility for risk stratification and personalized therapeutic strategies.展开更多
文摘消费者体验需求的提升促使零售商不断探索新渠道模式,以提高原有实体店效益的同时优化线上经营策略。本文分别考虑传统BORO(buy online and return online)和开通BOPS(buy online and pickup in store)两种渠道情形,构建零售商针对消费者线上购买并在线上或线下退款的差异化退货策略利润模型,分析两种渠道情形下的最优定价和最优退货策略,进而考虑BOPS渠道的溢出效应,分析零售商在相同退货策略下是否应该开通BOPS渠道。结果表明:(1)在两种情形下,随着线下商店数量的增多,零售商均会倾向于在低开店成本下选择全额退款策略,倾向于在高开店成本下选择部分退款策略;(2)在同渠道情形下,全额退款策略的定价始终低于部分退款策略。在同退货策略下,BOPS情形下的定价始终低于BORO情形;(3)高溢出效应和多商店数量都促使零售商选择开通BOPS渠道,但商店数量决定了BOPS线下麻烦成本规模因子对零售商开通BOPS渠道起推动还是抑制作用。本文为既定商店数量下多渠道零售商退货策略与渠道选择提供了决策支持。
基金supported by Young Talents Cultivation Program of Xianning City,the Natural Science Foundation of Hubei Province,China(No.2024AFB502)Ph.D.Start-up Funding(No.BK202413)Medical Fund(No.2023YKY04)of Hubei University of Science and Technology.
文摘Background:Kidney renal clear cell carcinoma(KIRC),a prevalent urological malignancy,represents about 3%of all adult malignancies.KIRC,accounting for~75%of renal malignancies,has poor prognosis in metastatic stages.Identifying robust prognostic markers remains urgent.Block of proliferation 1(BOP1),a WD40-repeat protein,is implicated in cancer pathogenesis,but its role in KIRC is unclear.This study aimed to characterize BOP1 expression in KIRC and evaluate its prognostic value.Methods:BOP1 transcriptional levels were assessed through TCGA-KIRC RNA sequencing datasets.ROC curve construction was implemented via R statistical packages for diagnostic evaluation.Patient survival outcomes were visualized through Kaplan-Meier plotting with log-rank testing.Multivariate logistic regression models quantified associations between BOP1 expression and clinicopathological parameters.TIMER algorithm analyzed immune microenvironment composition.Genomic alterations and epigenetic modifications were investigated using cBioPortal and MethSurv platforms respectively.BOP1 protein levels in 786-O clear cell renal cell carcinoma(ccRCC)versus HK-2(normal renal)cell lines were validated by immunoblotting.Results:Evaluation of the TCGA database demonstrated that BOP1 mRNA abundance was higher in tumor specimens than in corresponding adjacent tissues.Patients with KIRC who had high BOP1 expression had differential overall survival(OS),disease-specific survival(DSS),and disease-free interval(DFI).BOP1 expression accurately recognised tumour tissues versus normal tissues(AUC=0.858),and the area under the ROCs for survival at 1,3,and 5 years were all greater than 0.6.The BOP1 gene variant rate was<1%.Out of the 15 DNA methylation CpG sites examined,7 exhibited prognostic significance in KIRC.BOP1 displayed a distinct relationship with immune cell infiltration in KIRC.The 786-O experimental group exhibited substantially higher BOP1 expression,as confirmed by Western blot detection.Conclusion:This study indicates that heightened BOP1 expression is linked to an adverse prognosis in KIRC,establishing it as an independent risk factor for this disease.These findings establish BOP1 as a novel and independent prognostic biomarker for KIRC,offering potential clinical utility for risk stratification and personalized therapeutic strategies.
